HARMONY BIOSCIENCES PRESENTS NEW SECONDARY OUTCOME DATA FROM PHASE 2 SIGNAL DETECTION STUDY IN PATIENTS WITH PRADER-WILLI SYNDROME

/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and...

Related Keywords

United States ,Kumar Budur ,Luis Sanay ,Paragon Biosciences ,Foundation For Prader Willi Research ,Exchange Commission ,Prnewswire Harmony Biosciences Holdings Inc ,Drug Administration ,Company Nasdaq ,Biosciences Holdings ,Prader Willi Research ,Aberrant Behavioral ,Chief Medical Officer ,Secondary Outcomes ,Placebo Controlled Signal Detection ,Proof Of Concept Study ,Prader Willi Syndrome ,Caregiver Global Impression ,Aberrant Behavior ,Hyperphagia Questionnaire ,Clinical Trials ,Food Safe Zone ,About Prader Willi ,Full Prescribing Information ,Harmony Biosciences ,Plymouth Meeting ,Private Securities Litigation Reform Act ,Annual Report ,Biosciences Media Contact ,Biosciences Investor Contact ,